CHU Toulouse receives CTA Approval to initiate ALLOFIST, a Phase 1/2 Trial based on Cell-Easy’s proprietary adipose-derived MSC in Patients suffering from Crohn Disease - https://bioinformant.com/chu-toulouse-cell-easy-allofist/
Comments
Log in with your Bluesky account to leave a comment
Comments